Cargando…
Genetic Variation in CCL18 Gene Influences CCL18 Expression and Correlates with Survival in Idiopathic Pulmonary Fibrosis—Part B
Idiopathic pulmonary fibrosis (IPF) is a progressive disease with high mortality. CC-chemokine ligand 18 (CCL18) is predictive of survival in IPF. We described correlation of CCL18 serum levels with the genotype of rs2015086 C > T polymorphism the CCL18-gene, which was associated with survival in...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7356861/ https://www.ncbi.nlm.nih.gov/pubmed/32630441 http://dx.doi.org/10.3390/jcm9061993 |
_version_ | 1783558579580567552 |
---|---|
author | Caliskan, Canay Seeliger, Benjamin Jäger, Benedikt Fuge, Jan Welte, Tobias Terwolbeck, Oliver Freise, Julia van Moorsel, Coline H. M. Zhang, Yingze Prasse, Antje |
author_facet | Caliskan, Canay Seeliger, Benjamin Jäger, Benedikt Fuge, Jan Welte, Tobias Terwolbeck, Oliver Freise, Julia van Moorsel, Coline H. M. Zhang, Yingze Prasse, Antje |
author_sort | Caliskan, Canay |
collection | PubMed |
description | Idiopathic pulmonary fibrosis (IPF) is a progressive disease with high mortality. CC-chemokine ligand 18 (CCL18) is predictive of survival in IPF. We described correlation of CCL18 serum levels with the genotype of rs2015086 C > T polymorphism the CCL18-gene, which was associated with survival in a pre-antifibrotic cohort (Part-A). Herein (Part-B), we aimed to validate these findings and to study the effects of antifibrotics. Two cohorts were prospectively recruited, cohort-A (n = 61, pre-antifibrotic) and cohort B (n = 101, received antifibrotics). Baseline CCL18 serum level measurement by enzyme-linked immunosorbent assay (ELISA, serially in cohort B) and genotyping of rs2015086 was performed and correlated with clinical outcomes. The CT genotype was present in 15% and 31% of patients. These patients had higher CCL18 levels compared to the TT-genotype (cohort-A: 234 vs. 115.8 ng/mL, p < 0.001; cohort B: 159.5 vs. 120 ng/mL, p = 0.0001). During antifibrotic therapy, CCL18 increased (p = 0.0036) regardless of rs2015086-genotype and antifibrotic-agent. In cohort-A, baseline CCL18-cutoff (>120 ng/mL) and CT-genotype were associated with mortality (p = 0.041 and p = 0.0051). In cohort-B, the CCL18-cutoff (>140 ng/mL) was associated with mortality (p = 0.003) and progression (p = 0.004), but not the CT/CC-genotype. In conclusion, we validated the correlation between rs2015086-genotype and CCL18 serum levels, which was predictive of (progression-free)-survival in two prospective validation cohorts. |
format | Online Article Text |
id | pubmed-7356861 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-73568612020-07-22 Genetic Variation in CCL18 Gene Influences CCL18 Expression and Correlates with Survival in Idiopathic Pulmonary Fibrosis—Part B Caliskan, Canay Seeliger, Benjamin Jäger, Benedikt Fuge, Jan Welte, Tobias Terwolbeck, Oliver Freise, Julia van Moorsel, Coline H. M. Zhang, Yingze Prasse, Antje J Clin Med Article Idiopathic pulmonary fibrosis (IPF) is a progressive disease with high mortality. CC-chemokine ligand 18 (CCL18) is predictive of survival in IPF. We described correlation of CCL18 serum levels with the genotype of rs2015086 C > T polymorphism the CCL18-gene, which was associated with survival in a pre-antifibrotic cohort (Part-A). Herein (Part-B), we aimed to validate these findings and to study the effects of antifibrotics. Two cohorts were prospectively recruited, cohort-A (n = 61, pre-antifibrotic) and cohort B (n = 101, received antifibrotics). Baseline CCL18 serum level measurement by enzyme-linked immunosorbent assay (ELISA, serially in cohort B) and genotyping of rs2015086 was performed and correlated with clinical outcomes. The CT genotype was present in 15% and 31% of patients. These patients had higher CCL18 levels compared to the TT-genotype (cohort-A: 234 vs. 115.8 ng/mL, p < 0.001; cohort B: 159.5 vs. 120 ng/mL, p = 0.0001). During antifibrotic therapy, CCL18 increased (p = 0.0036) regardless of rs2015086-genotype and antifibrotic-agent. In cohort-A, baseline CCL18-cutoff (>120 ng/mL) and CT-genotype were associated with mortality (p = 0.041 and p = 0.0051). In cohort-B, the CCL18-cutoff (>140 ng/mL) was associated with mortality (p = 0.003) and progression (p = 0.004), but not the CT/CC-genotype. In conclusion, we validated the correlation between rs2015086-genotype and CCL18 serum levels, which was predictive of (progression-free)-survival in two prospective validation cohorts. MDPI 2020-06-25 /pmc/articles/PMC7356861/ /pubmed/32630441 http://dx.doi.org/10.3390/jcm9061993 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Caliskan, Canay Seeliger, Benjamin Jäger, Benedikt Fuge, Jan Welte, Tobias Terwolbeck, Oliver Freise, Julia van Moorsel, Coline H. M. Zhang, Yingze Prasse, Antje Genetic Variation in CCL18 Gene Influences CCL18 Expression and Correlates with Survival in Idiopathic Pulmonary Fibrosis—Part B |
title | Genetic Variation in CCL18 Gene Influences CCL18 Expression and Correlates with Survival in Idiopathic Pulmonary Fibrosis—Part B |
title_full | Genetic Variation in CCL18 Gene Influences CCL18 Expression and Correlates with Survival in Idiopathic Pulmonary Fibrosis—Part B |
title_fullStr | Genetic Variation in CCL18 Gene Influences CCL18 Expression and Correlates with Survival in Idiopathic Pulmonary Fibrosis—Part B |
title_full_unstemmed | Genetic Variation in CCL18 Gene Influences CCL18 Expression and Correlates with Survival in Idiopathic Pulmonary Fibrosis—Part B |
title_short | Genetic Variation in CCL18 Gene Influences CCL18 Expression and Correlates with Survival in Idiopathic Pulmonary Fibrosis—Part B |
title_sort | genetic variation in ccl18 gene influences ccl18 expression and correlates with survival in idiopathic pulmonary fibrosis—part b |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7356861/ https://www.ncbi.nlm.nih.gov/pubmed/32630441 http://dx.doi.org/10.3390/jcm9061993 |
work_keys_str_mv | AT caliskancanay geneticvariationinccl18geneinfluencesccl18expressionandcorrelateswithsurvivalinidiopathicpulmonaryfibrosispartb AT seeligerbenjamin geneticvariationinccl18geneinfluencesccl18expressionandcorrelateswithsurvivalinidiopathicpulmonaryfibrosispartb AT jagerbenedikt geneticvariationinccl18geneinfluencesccl18expressionandcorrelateswithsurvivalinidiopathicpulmonaryfibrosispartb AT fugejan geneticvariationinccl18geneinfluencesccl18expressionandcorrelateswithsurvivalinidiopathicpulmonaryfibrosispartb AT weltetobias geneticvariationinccl18geneinfluencesccl18expressionandcorrelateswithsurvivalinidiopathicpulmonaryfibrosispartb AT terwolbeckoliver geneticvariationinccl18geneinfluencesccl18expressionandcorrelateswithsurvivalinidiopathicpulmonaryfibrosispartb AT freisejulia geneticvariationinccl18geneinfluencesccl18expressionandcorrelateswithsurvivalinidiopathicpulmonaryfibrosispartb AT vanmoorselcolinehm geneticvariationinccl18geneinfluencesccl18expressionandcorrelateswithsurvivalinidiopathicpulmonaryfibrosispartb AT zhangyingze geneticvariationinccl18geneinfluencesccl18expressionandcorrelateswithsurvivalinidiopathicpulmonaryfibrosispartb AT prasseantje geneticvariationinccl18geneinfluencesccl18expressionandcorrelateswithsurvivalinidiopathicpulmonaryfibrosispartb |